Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Busse

Showing results (211-220 of 241) with videos related to

Pageof 25
Sort By:
The World Allergy Organization Journal|January 4, 2013
Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategiesRichard G Gower, Paula J Busse, Emel Aygören-Pürsün, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 8, 2020
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary AngioedemaPaula J Busse, Sandra C Christiansen, Marc A Riedl, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|May 29, 2023
A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxisJoan Mendivil, Maral DerSarkissian, Aleena Banerji, et al.
American Journal of Respiratory and Critical Care Medicine|January 16, 2015
Blue journal conference. Aging and susceptibility to lung diseaseVictor J Thannickal, Mahadev Murthy, William E Balch, et al.
Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)|October 2, 2025
[Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE]Inmaculada Martinez-Saguer, Andrea Zanichelli, Emel Aygören-Pürsün, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 19, 2025
Authors' responseAndrea Zanichelli, Walter A Wuillemin, Aleena Banerji, et al.
Annals of the American Thoracic Society|November 11, 2016
An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the ElderlyGwen S Skloot, Paula J Busse, Sidney S Braman, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 6, 2025
Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidenceAndrea Zanichelli, Walter A Wuillemin, Emel Aygören-Pürsün, et al.
Advances in Therapy|June 12, 2025
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World StudyJonathan A Bernstein, Stephen D Betschel, Paula J Busse, et al.
Allergy|October 20, 2018
American Academy of Allergy, Asthma and Immunology response to the EAACI/GA<sup>2</sup> LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of Urticaria 2017 revisionRobert A Wood, David A Khan, David M Lang, et al.
Pageof 25

Showing results (211-220 of 241) with videos related to

Sort By:
Pageof 25
The World Allergy Organization Journal|January 4, 2013
Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategiesRichard G Gower, Paula J Busse, Emel Aygören-Pürsün, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 8, 2020
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary AngioedemaPaula J Busse, Sandra C Christiansen, Marc A Riedl, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|May 29, 2023
A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxisJoan Mendivil, Maral DerSarkissian, Aleena Banerji, et al.
American Journal of Respiratory and Critical Care Medicine|January 16, 2015
Blue journal conference. Aging and susceptibility to lung diseaseVictor J Thannickal, Mahadev Murthy, William E Balch, et al.
Revista Alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)|October 2, 2025
[Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE]Inmaculada Martinez-Saguer, Andrea Zanichelli, Emel Aygören-Pürsün, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 19, 2025
Authors' responseAndrea Zanichelli, Walter A Wuillemin, Aleena Banerji, et al.
Annals of the American Thoracic Society|November 11, 2016
An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the ElderlyGwen S Skloot, Paula J Busse, Sidney S Braman, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 6, 2025
Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidenceAndrea Zanichelli, Walter A Wuillemin, Emel Aygören-Pürsün, et al.
Advances in Therapy|June 12, 2025
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World StudyJonathan A Bernstein, Stephen D Betschel, Paula J Busse, et al.
Allergy|October 20, 2018
American Academy of Allergy, Asthma and Immunology response to the EAACI/GA<sup>2</sup> LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of Urticaria 2017 revisionRobert A Wood, David A Khan, David M Lang, et al.
Pageof 25